Condition: Non-small-cell Lung Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
Objective to compare the efficacy and safety of TQB2450 injection combined with anlotinib and chemotherapy, and TQB2450 injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer subjects who failed to receive first-line chemotherapy combined with immunization, and to explore and evaluate biomarkers related to efficacy, mechanism of action / resistance mechanism, and safety.
This description comes directly from the study's public registry record.
Kai Li, doctor · 18622221218 · likai@tjmuch.com
Always discuss trial participation with your own doctor first.
| The Central People's Hospital of Huizhou | Huizhou, Guangdong, China | Not Yet Recruiting |
| The First Affiliated Hospital of Nanyang Medical College | Nanyang, Henan, China | Recruiting |
| The Second People's Hospital of Lianyungang | Lianyungang, Jiangsu, China | Recruiting |
| Weihai Municipal Hospital | Weihai, Shandong, China | Not Yet Recruiting |
| Tianjin Medical University Cancer Institute and Hospital | Tianjin, Tianjin Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06141226